GlobeNewswire by notified

SpaceX CRS-24 Launching Multiple Life Science Investigations to the International Space Station

Share

Cape Canaveral, FL, Dec. 16, 2021 (GLOBE NEWSWIRE) -- The microgravity environment on the International Space Station (ISS) has a profound impact on cells and tissues, allowing researchers to conduct life sciences research in ways not possible on the ground. SpaceX’s 24th Commercial Resupply Services (CRS) mission to the orbiting laboratory will deliver a variety of life science payloads sponsored by the ISS National Laboratory (managed by the Center for the Advancement of Science in Space). From stem cell research on neurodegenerative diseases to a tissue chip experiment studying the blood-brain barrier and an investigation testing the use of bacteria to protect DNA from the stresses of spaceflight—the research launching on this mission is helping to improve the quality of life for people on Earth.

Microgravity affects organisms—from bacteria to humans—inducing changes such as altered gene expression and DNA regulation, changes in cellular function and physiology, and 3D aggregation of cells. Research leveraging these effects can drive advances in pharmaceutical development, disease modeling, regenerative medicine, and many other areas within the life sciences. Below are highlights of several life sciences investigations sponsored by the ISS National Laboratory that are launching on SpaceX CRS-24.

The National Stem Cell Foundation is collaborating with the Exomedicine Institute on a unique 3D study of neurodegeneration in the absence of gravity using cells from patients with primary progressive multiple sclerosis (PPMS) and Parkinson’s disease (PD). This marks the first time that disease-specific cells from patients with PPMS and PD will be studied on the ISS to observe the cell-to-cell interactions of neurodegeneration and neuroinflammation when the gravitational forces affecting cells on Earth are removed. Results from this investigation, which is supported by ISS National Lab Commercial Service Provider Space Tango, could further enhance knowledge regarding the genetic makeup of these debilitating diseases.

Boston-based pharmaceutical company Emulate is launching an investigation using proprietary tissue chip technology to examine the effects of microgravity on the blood-brain barrier. This project, funded by the National Center for Advancing Translational Sciences (part of the National Institutes of Health), builds on an initial tissue chip investigation that Emulate launched in 2019. Tissue chips contain human cells grown on an artificial scaffold to model the structure and function of human tissue. For this study, Emulate will use its Brain-Chip, which consists of living neuronal and vascular endothelial cells in a micro-engineered environment. The blood-brain barrier is a semi-permeable barrier that allows selective passage of certain molecules and gases while preventing the passage of others. It is a critical component involved in maintaining homeostasis, and disruption of the barrier can lead to or cause neurological dysfunction or disease. Results from this investigation, which is also supported by Space Tango, may provide insight into the relationship between inflammation and brain function, leading to a better understanding of neurodegenerative diseases such as Alzheimer’s and Parkinson’s.

DNA components are integral to synthetic biology and bioengineering of organisms for a variety of applications, such as producing pharmaceuticals, improving consumer products, and developing clean plastics. An investigation from ISS National Lab Commercial Service Provider Rhodium Scientific, in collaboration with Lawrence Berkeley National Laboratory, will test the use of specific bacterial strains to protect and preserve DNA during the stresses of launch, in-orbit stowage, and return to Earth. Results could help to create more rugged biological components and advance these technologies for use in space and in extreme environments on Earth.

These are only a few of the ISS National Lab-sponsored investigations launching on SpaceX CRS-24. This mission, contracted by NASA, is slated to launch no earlier than December 21 at 5:06 a.m. EST from NASA’s Kennedy Space Center. To learn more about all ISS National Lab-sponsored research launching on this mission, please visit our launch page.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Fingerprint Cards AB: inbjudan till presentation av resultatet för fjärde kvartalet 202121.1.2022 09:00:00 CET | Pressemelding

FingerprintCardsAB (Fingerprints™)bjuder in till telefonkonferens och en webbsänd presentation av resultatet för fjärde kvartalet 2021, den 28 januari 2022klockan 09:00 CET. Fingerprints vd Christian Fredrikson presenterar rapporten tillsammans med CFO Per Sundqvist i en kombinerad webbsändning och telefonkonferens. Presentationen sker på engelska. Tid: fredagen den 28 januari 2022, klockan 09:00 CET. Plats: kombinerad webbsändning och telefonkonferens. Rapporten finns på https://www.fingerprints.com/ Webbsändningen och presentationsmaterialet finns på https://edge.media-server.com/mmc/p/ae2ki69u där man även har möjlighet att ställa frågor. För media och analytiker: Telekonferensen nås via +44 (0) 2071 928000 (internationella deltagare) eller 08-506 921 80 (svenska deltagare). V.g. uppge konferens-ID 6498218. Om Fingerprints Fingerprint Cards AB (Fingerprints) - det ledande globala biometribolaget med svenska rötter. Vi tror på en säker och sammanbunden värld, där du är nyckeln till a

Fingerprint Cards AB: invitation to the fourth quarter 2021 results presentation21.1.2022 09:00:00 CET | Press release

Fingerprint Cards AB (Fingerprints™) will host a telephone conference and webcast presentation of its fourth quarter 2021 results, on January28, 2022 at 09:00 am CET. Fingerprints’ CEO Christian Fredrikson will present the report together with CFO Per Sundqvist in a combined webcast and telephone conference. The presentation will be held in English. Time: Friday, January 28, 2022 at 09:00 am CET. Location: combined webcast and telephone conference. The report is available at https://www.fingerprints.com/ The webcast and the presentation material can be accessed through https://edge.media-server.com/mmc/p/ae2ki69u where it is also possible to ask questions. For media and analysts: The telephone conference dial-in is +44 (0) 2071 928000 (international participants) or 08-506 921 80 (Swedish participants). Please state conference ID 6498218. About Fingerprints Fingerprint Cards AB (Fingerprints) – the world’s leading biometrics company, with its roots in Sweden. We believe in a secure and

Scandinavian Tobacco Group A/S: Major Shareholders Announcement21.1.2022 08:45:00 CET | Press release

Company Announcement No. 4/2022 Copenhagen, 21 January 2022 Major Shareholder’s Announcement With reference to Section 38 of the Danish Act on Capital Markets (kapitalmarkedsloven)) it is hereby announced that Capital Group Companies, Inc has informed Scandinavian Tobacco Group A/S (the “Company”) that funds administered by companies within Capital Group Companies, Inc on 19 January 2022 control shares in total amounting to more than 5% of the Company’s share capital and Capital Group Companies, Inc exercises more than 5% of the voting rights. Funds administered by Capital Group Companies, Inc thus control 4,921,237 shares with a nominal value of DKK 1 (aggregate nominal value DKK 4,921,237), corresponding to 5.05% of the total share capital, and on behalf of these funds Capital Group Companies, Inc exercises 5.05% of the voting rights. For further information, please contact: Investors: Torben Sand, Head of Investor Relations, phone: +45 5084 7222 or torben.sand@st-group.com Media: Si

Wolters Kluwer appoints new Chair and new Vice-Chair of the Supervisory Board21.1.2022 08:30:00 CET | Press release

Wolters Kluwer appointsnew Chair and new Vice-Chair of the Supervisory Board January21, 2022–Wolters Kluwer today announcesthe appointmentper April 21, 2022 of Ann Ziegleras Chair of the Supervisory Board. As previously disclosed, Chair Mr. Cremers will retire from the Board at the close ofthe Annual General Meeting of Shareholders. Member of the Supervisory Board Jack de Kreijis appointed to succeed Mrs. Ziegler as Vice-Chair of the Board. Ann Ziegler was appointed in 2017 and is currently Vice-Chair of the Supervisory Board and a member of the Selection and Remuneration Committee. Jack de Kreij was appointed in 2020 and is Chair of the Audit Committee. Chair of the Supervisory Board Frans Cremers commented: “We are very pleased to nominate Ms. Ziegler and Mr. De Kreij for appointment on their new roles in the Supervisory Board. Their extensive experience at several publicly-listed international companies in different industries will be of indispensable value. The composition of the S

Överumans Fisk AB, a Swedish subsidiary of AS PRFoods, borrows money to kick-start a fish farming and to support its working capital21.1.2022 08:08:55 CET | Press release

Överumans Fisk AB, a subsidiary of AS PRFoods, entered into loan agreements with Amber Trust II S.C.A., SICAR and Lindermann, Birnbaum & Kasela OÜ to borrow up to EUR 1,000,000 (up to EUR 500,000 from each lender). The repayment term of both loans is 31.12.2022 and the interest is 6.25% per annum. The money is borrowed to support the start-up phase of Swedish fish farming and to boost company's working capital at the same time. Fish will be farmed in Sweden's largest and most environmentally friendly farm, using predominantly hydroelectric power or other renewable energy sources. The CO2 footprint of the fish farm is also about 1/3 smaller than, for example, in RAS-type i.e. terrestrial farms. The lenders are the shareholders of AS PRFoods and thus the related persons within the meaning of the “Requirements for Issuers” regulations of the Nasdaq Tallinn Stock Exchange. Indrek Kasela AS PRFoods Member of the Management Board Phone: +372 452 1470 investor@prfoods.ee www.prfoods.ee

Better Collective enters into commercial partnership with The New York Post21.1.2022 08:00:00 CET | Press release

Regulatory release 5/2022 January 21, 2022 The world leading sports betting media group, Better Collective (NASDAQ: BETCO.STO), signs an agreement with the New York Post to deliver innovative technology and commercial content for online sports betting through its proprietary sports betting platform, Action Network. Better Collective, the world’s leading sports betting media group, is joining forces with the New York Post to bring the best in commercial sports betting content to the publication’s readership of more than 92 million unique users. More than 11 million unique users come from New York state, which recently regulated online betting. The agreement is for the delivery of content, data, and statistics for the betting section of the New York Post. The commercial partnership includes Better Collective delivering its innovative technology and content for sports betting to educate and empower the US audience of online bettors and help them navigate in a market that is growing fast a

Scanfil expands its Wutha factory in Germany by 50%21.1.2022 08:00:00 CET | Press release

Scanfil plc Press Release 21 January 2022 at 8.00 a.m. CET Scanfilexpands its Wutha factory in Germany by 50% Scanfil’s factory in Wutha-Farnroda in Germany will increase by 2,200 m². The expansion is estimated to be in production use during the second quarter of 2022. The existing factory is 4,500 m² and employs approximately 270 professionals. “We are glad to announce us growing in Wutha, in the heart of Germany. Our factory is well located and close to our customers and their R&D,” the CEO of Scanfil Petteri Jokitalo states. “Growth expectations have improved significantly and gave us the confidence to invest more in Wutha.” The adjoining building is now under construction to meet an EMS service provider's high-quality requirements. Some of our customers in Wutha come from the medical sector, which has the most demanding standard for production quality and precision. “The majority of our customers come from the automation and safety sector, but there are also good growth prospects i